BR112022015303A2 - Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos - Google Patents

Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos

Info

Publication number
BR112022015303A2
BR112022015303A2 BR112022015303A BR112022015303A BR112022015303A2 BR 112022015303 A2 BR112022015303 A2 BR 112022015303A2 BR 112022015303 A BR112022015303 A BR 112022015303A BR 112022015303 A BR112022015303 A BR 112022015303A BR 112022015303 A2 BR112022015303 A2 BR 112022015303A2
Authority
BR
Brazil
Prior art keywords
nash
alcoholic steatohepatitis
biomarkers
individual
hepatic
Prior art date
Application number
BR112022015303A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexander Leigh
Ostroff Rachel
Field Stuart
Original Assignee
Somalogic Operating Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Operating Co Inc filed Critical Somalogic Operating Co Inc
Publication of BR112022015303A2 publication Critical patent/BR112022015303A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/08Hepato-biliairy disorders other than hepatitis
    • G01N2800/085Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022015303A 2020-02-10 2021-02-09 Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos BR112022015303A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062972418P 2020-02-10 2020-02-10
PCT/US2021/017217 WO2021163034A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
BR112022015303A2 true BR112022015303A2 (pt) 2022-09-27

Family

ID=74858782

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015303A BR112022015303A2 (pt) 2020-02-10 2021-02-09 Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos

Country Status (12)

Country Link
US (1) US20230071234A1 (https=)
EP (1) EP4103948A1 (https=)
JP (2) JP7766605B2 (https=)
KR (1) KR20220140727A (https=)
CN (1) CN115066616A (https=)
AU (1) AU2021220787A1 (https=)
BR (1) BR112022015303A2 (https=)
CA (2) CA3300793A1 (https=)
IL (1) IL295064A (https=)
MX (1) MX2022009517A (https=)
PH (1) PH12022552003A1 (https=)
WO (1) WO2021163034A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患(nafld)または非アルコール性脂肪肝炎(nash)を診断するためのマーカー
WO2025090996A1 (en) * 2023-10-28 2025-05-01 Novelna Inc. Nafld detection proteins and methods of use thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7824871B2 (en) * 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
JP5781436B2 (ja) * 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP3110976B1 (en) * 2014-02-27 2020-05-13 Biogen MA Inc. Method of assessing risk of pml
CA2978696A1 (en) * 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Novel methods for early identification of bone healing ability in injured patients
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
KR20180029046A (ko) * 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
CN107923918A (zh) * 2015-09-09 2018-04-17 私募蛋白质体公司 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
US20210215711A1 (en) * 2016-02-08 2021-07-15 Somalogic, Inc. Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
CN111183360B (zh) * 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合

Also Published As

Publication number Publication date
CA3166923A1 (en) 2021-08-19
JP2023512701A (ja) 2023-03-28
IL295064A (en) 2022-09-01
US20230071234A1 (en) 2023-03-09
KR20220140727A (ko) 2022-10-18
PH12022552003A1 (en) 2024-02-05
AU2021220787A1 (en) 2022-09-01
CN115066616A (zh) 2022-09-16
JP2026021411A (ja) 2026-02-10
WO2021163034A1 (en) 2021-08-19
EP4103948A1 (en) 2022-12-21
CA3300793A1 (en) 2026-03-02
MX2022009517A (es) 2022-09-02
JP7766605B2 (ja) 2025-11-10

Similar Documents

Publication Publication Date Title
EP4513191A3 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
BR112022015303A2 (pt) Biomarcadores de esteato-hepatite não alcoólica (nash) e usos dos mesmos
BR112012019872A2 (pt) composicao de detergente
MX388508B (es) Composicion farmacéutica que comprende un agonista fxr y un fibrato (agonista ppar-alfa).
BRPI0607556A2 (pt) sistemas e métodos que combinam serviços de subscrição, programas de prêmios, e loteria
BR112015001601A2 (pt) células de levedura tendo curso de tca redutor de piruvato em succinato e superexpressão de uma enzima transidrogenase nad(p)+ exógena
BR112015020098A2 (pt) método e composição para coloração e processamento de amostras
BR112013000110A2 (pt) composições de limpeza e processo de limpeza
BR112014004444A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BRPI0906104B8 (pt) derivado de ácido peptonucleico, composição farmacêutica contendo uma quantidade terapeuticamente eficaz do derivado de ácido peptonucleico, método de utilização do derivado de ácido peptonucleico e composto
BR112013000114A2 (pt) composição de limpeza e processo para limpeza de um substrato
BR112014029442A2 (pt) composições antimucosas à base de xilitol e métodos e composições relacionados
BR112012018163A2 (pt) métodos e composições para exibição de um polipeptídeo sobre a superfície de uma célula de levredura
WO2006023966A3 (en) Assessment of cardiovascular risk
BR112012012476A2 (pt) "composições nutritivas incluindo um componente de alta proteína e nucleotídeos exôgenos"
BR112015015371A2 (pt) realçador de aparência para composições de borracha com antidegradantes
NZ586423A (en) Liver function-protecting agent comprising a phospholipid
MX2020006012A (es) Composiciones de arni de la caja 1 del grupo de alta movilidad (hmgb1) y métodos de uso de las mismas.
EP2197455A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING INHIBITORS OF RETROVIRAL INFECTIONS
BR112017025503A2 (pt) composições à base de polímero preenchido com baixa viscosidade, boas propriedades mecânicas e adesão
BR112022013774A2 (pt) Composição agrotóxica estável
BRPI0518414A2 (pt) dispositivo para troca de calor para gases com teor de Ácido
BR112012010392A2 (pt) composição, método e kit para o inibidor de alfa-1 proteinase
WO2006096735A8 (en) Enhancing a luminescent signal
BR112019001544A2 (pt) composições poliméricas expansíveis em bloco